In type 1 diabetes, which of the following is true: (1) insulin is required for all patients at stage 3 disease; (2) the recommended starting basal‑to‑bolus insulin ratio for a newly diagnosed insulin‑naïve patient is 50:50; (3) teplizumab (generic) is FDA‑approved to delay progression from stage 2 to stage 3 in patients aged 8 years and older; and (4) metformin is a reasonable adjunct therapy for a stage 3 patient experiencing frequent hypoglycemia despite optimal education and disease management?

Type 1 Diabetes: Insulin Requirements, Initial Dosing, Teplizumab, and Management of Refractory Hypoglycemia

Question 1: Insulin Requirements by Stage

Insulin is required for all patients beginning in stage 3 T1D (answer b). Stage 3 type 1 diabetes is defined by symptomatic hyperglycemia requiring insulin therapy, and this applies universally to both children and adults 1, 2.

• Stage 2 T1D is characterized by the presence of islet autoantibodies and dysglycemia without overt hyperglycemia—insulin is not yet required at this stage 3, 4.
• Stage 3 T1D represents clinical diabetes with symptomatic hyperglycemia due to significant beta-cell destruction, making insulin replacement mandatory for survival 2, 5.
• All individuals with stage 3 T1D—regardless of age—require lifelong insulin therapy 1, 2.

---

Question 2: Starting Basal-to-Bolus Insulin Ratio

The recommended starting ratio of basal insulin to bolus insulin for newly diagnosed, insulin-naïve patients with T1D is 50:50 (answer c).

• In general, individuals with type 1 diabetes require 50% of their daily insulin as basal and 50% as prandial insulin 1.
• The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook notes 0.5 units/kg/day as a typical starting dose in metabolically stable individuals, with half administered as prandial insulin and the other half as basal insulin 1.
• Total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day, with higher amounts required during puberty, pregnancy, and medical illness 1, 6, 1.
• This 50:50 split is dependent on individual factors including carbohydrate intake patterns, but serves as the standard initial approach 1.

---

Question 3: FDA-Approved Therapy to Delay Stage 3 T1D

Teplizumab (answer a) is the FDA-approved therapy to delay the onset of stage 3 T1D in adults and pediatric patients 8 years and older with stage 2 T1D.

• Teplizumab-mzwv is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes 4.
• Teplizumab is a CD3-directed humanized monoclonal antibody that binds to CD3 on T lymphocytes and delays progression through partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes 4.
• In the pivotal TN-10 trial, the median time to stage 3 T1D diagnosis was 48.4 months in the teplizumab group versus 24.4 months in the placebo group (HR 0.41 [95% CI 0.22–0.78]) 3.
• Treatment consists of a 14-day intravenous infusion course with body surface area-based dosing 4.
• The other options listed are not FDA-approved for this indication: insulin glargine is used for treatment (not delay) of stage 3 disease 1, while donislecel and abatacept are not approved for type 1 diabetes prevention 3.

---

Question 4: Management of Refractory Hypoglycemia in Stage 3 T1D

Donislecel (answer d) is a reasonable therapeutic option for a patient with stage 3 T1D experiencing frequent hypoglycemic episodes despite optimal disease management and education.

Rationale for Donislecel (Islet or Pancreas Transplantation):

• For patients with stage 3 T1D whose problematic hypoglycemia persists despite education, diabetes technology, and intensive management, islet or pancreas transplant should be considered 7.
• Problematic hypoglycemia is defined as two or more episodes per year of severe hypoglycemia or one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior 7.
• A tiered algorithm recommends: (1) structured hypoglycemia-specific education, (2) adding one diabetes technology (CGM or insulin pump), (3) sensor-augmented pumps with low-glucose suspend, and finally (4) islet or pancreas transplantation for refractory cases 7.

Why Not the Other Options:

• Metformin (answer a) is NOT appropriate: While metformin can reduce insulin requirements and improve metabolic control in overweight/obese patients with poorly controlled type 1 diabetes, it does not improve glycemic control (absolute A1C reduction 0.11%, P = 0.42) and is not indicated for hypoglycemia management 8, 9.
• Increased basal insulin dose (answer b) would worsen hypoglycemia: Increasing insulin in a patient already experiencing frequent hypoglycemia despite optimal management would increase hypoglycemia risk further 10, 7.
• Teplizumab (answer c) is only approved for stage 2 T1D to delay progression to stage 3, not for treatment of established stage 3 disease with hypoglycemia 3, 4.

Additional Management Considerations:

• Patients with hypoglycemia unawareness or level 3 hypoglycemia should raise glycemic targets to strictly avoid hypoglycemia for at least several weeks to partially reverse hypoglycemia unawareness 10.
• Sensor-augmented insulin pumps with automated low-glucose suspend features should be considered for patients with frequent nocturnal hypoglycemia and/or hypoglycemia unawareness 9, 8, 1.
• Automated insulin delivery (AID) systems may improve time in range and reduce hypoglycemia 1.